Results 1 - 10 of 56 : 1 2 3 4 5 6 Next
What the Best Money Managers Are Doing Now
Should you follow their lead?
Invest selectively and defensively in times of turmoil.
The Mistake Everyone's Making Now
One strategy that looks attractive right now is actually incredibly bad.
Allergan's muscle relaxant Botox performs well in two studies.
The generic-drug company decides to keep its specialty pharmaceutical subsidiary.
Why Pfizer Made an Interesting Blockbuster Bet
Pfizer inks a rich deal to get a late-stage-drug candidate.
Maybe what glitters really is gold.
Barr and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
Me-Too Drugs: Are They Worth It?
These drugs have less risk, but also usually bring less of a reward.
Examining Elan's Ups and Downs
Was the pharmaceutical's news as bad as investors treated it?
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK